First MPS-VI patient dosed under Phase 2 trial in Brazil
Filed with ASX · · 3 pages · English
• The first MPS-VI participant has been dosed at Hospital de Clinicas de Porto Alegre, Brazil. • The study is evaluating PPS compared to placebo in up to 12 patients in a 2:1 randomization at two investigator sites in Brazil. • Primary objective of the study is to evaluate the safety and tolerability of PPS in subjects with MPS-VI at 6, 12 and 24 weeks. • Secondary endpoints will include reduction
Paradigm Biopharmaceuticals Ltd. on 6ix
Story so far
Earlier from Paradigm Biopharmaceuticals
- Paradigm receives feedback from US FDA on ind submission
- Aus ethics approval received for Phase 3 trial
- 2021 Annual Report and Appendix 4E
- Paradigm reports IND application update
- Paradigm submits responses to US FDA questions
Later from Paradigm Biopharmaceuticals
- Positive top-line results from preclinical study in ARDS
- Phase 2 Synovial Fluid Biomarker Study Update
- Paradigm cleared for phase 3 Trial by US FDA
- Paradigm CEO Paul Rennie to transition to Non-Exec Chairman
- Preliminary Results from Phase 2 MPS I Study
Follow Paradigm Biopharmaceuticals into a list and get an email when it puts out news.
Follow Paradigm Biopharmaceuticals